HAE
12
4
5
4
Key Insights
Highlights
Success Rate
80% trial completion
Clinical Risk Assessment
Based on trial outcomes
Low Risk
Score: 17/100
8.3%
1 terminated out of 12 trials
80.0%
-6.5% vs benchmark
42%
5 trials in Phase 3/4
75%
3 of 4 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 4 completed trials
Clinical Trials (12)
Single-center Randomized Controlled Trial of Rectal Arterial Embolization vs Band Ligation for the Treatment of Internal hemOrrhoidS
Phase 3 Extension Study of ADX-324 in Participants With Hereditary Angioedema (HAE)
STOP-HAE: A Phase 3 Study of ADX-324 in HAE
Hemorrhoidal Artery Embolization: Longitudinal Impact On Symptoms (HELIOS)
Open-label Berotralstat Access to HAE Patients Previously Enrolled in Berotralstat Studies
12-Week Safety and Efficacy Study of BCX4161 as an Oral Prophylaxis Against HAE Attacks
A Gene Therapy Study of BMN 331 in Subjects With Hereditary Angioedema
Efficacy and Safety Study of BCX7353 as an Oral Treatment for the Prevention of Attacks in HAE
A Long Term Safety Study of BCX7353 in Hereditary Angioedema
Biomarker for Hereditary AngioEdema Disease
Oral Berotralstat Expanded Access Program
Open-label, Long-term Safety Study of Avoralstat in Subjects With Hereditary Angioedema